Your browser doesn't support javascript.
loading
Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166.
Pedone, Maria Paola; Dobreva, Miryana; Bastian, Mike; Tavi, Jules; Noonan, Kerry.
Affiliation
  • Pedone MP; Sanofi, Milano, Italy.
  • Dobreva M; Sanofi, Milano, Italy.
  • Bastian M; Sanofi, Frankfurt, Germany.
  • Tavi J; Sanofi, Gentilly, France.
  • Noonan K; Sanofi, Cambridge, USA.
J Med Econ ; 27(1): 800-802, 2024.
Article in En | MEDLINE | ID: mdl-38842021
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Pyrazoles / Sulfonamides / Azetidines / Cost-Benefit Analysis / Dermatitis, Atopic / Antibodies, Monoclonal, Humanized Limits: Humans Country/Region as subject: Europa Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2024 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Pyrazoles / Sulfonamides / Azetidines / Cost-Benefit Analysis / Dermatitis, Atopic / Antibodies, Monoclonal, Humanized Limits: Humans Country/Region as subject: Europa Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2024 Document type: Article Affiliation country: